LIU Hao,YANG Yinglin,CAI Le,et al.Establishment of a standardized management model for postoperative anti-osteoporosis medication in patients with brittle fractures[J].ZHONGGUO YAOFANG,2025,36(15):1926-1930.
LIU Hao,YANG Yinglin,CAI Le,et al.Establishment of a standardized management model for postoperative anti-osteoporosis medication in patients with brittle fractures[J].ZHONGGUO YAOFANG,2025,36(15):1926-1930. DOI: 10.6039/j.issn.1001-0408.2025.15.19.
Establishment of a standardized management model for postoperative anti-osteoporosis medication in patients with brittle fractures
To investigate the establishment and promotion of a new standardized management model for anti-osteoporosis medication after fragility fracture surgery by resident clinical pharmacists, and provide references for resident pharmacists to carry out clinical pharmaceutical services.
METHODS
2
From July 2023 to March 2024,595 post-brittle fracture surgery patients were enrolled. Using the PDCA (plan-do-check-act) cycle,resident clinical pharmacists identified issues and conducted investigations in clinical practice. Through integrating clinical pharmacist intervention services before, during and after treatment, a medication treatment pathway was developed, thereby establishing a standardized management model for anti-osteoporosis treatment following fragility fracture surgery. Leveraging the National Brittle Fracture Big Data Platform (under the National Clinical Research Center for Orthopedics and Sports Rehabilitation), a dedicated data module was constructed, providing big data support to evaluate the efficacy of this pharmaceutical care model.
RESULTS
2
Continuous PDCA cycle driven improvements significantly increased the proportion of osteoporosis diagnosis (from 9% before intervention to 81%) and proportion of drug treatment (from 4% to 75%).The proportions of bone density and bone metabolism testing also rose markedly,positively impacting long-term patient outcomes.
CONCLUSIONS
2
The establishment of a standardized management model for anti-osteoporosis treatment following fragility fracture surgery by resident clinical pharmacists has enhanced clinicians’ diagnostic and therapeutic capabilities for osteoporosis, ensures rational medication use in osteoporosis patients, and demonstrates significant potential for widespread adoption and application.
DECLERCQ M G , EBERHARDT L , ZAKKO P , et al . Equivalence in osteoporosis workup and management after femoral neck fracture fixation and vertebral compression fracture cement augmentation:a single-center retrospective study highlighting persistent underdiagnosis and undertreatment [J ] . J Orthop , 2024 , 56 : 133 - 140 .
WEAVER J , SAJJAN S , LEWIECKI E M , et al . Diagnosis and treatment of osteoporosis before and after fracture:a side-by-side analysis of commercially insured and medicare advantage osteoporosis patients [J ] . J Manag Care Spec Pharm , 2017 , 23 ( 7 ): 735 - 744 .
YANG J C , TANG Q H , CHE M H , et al . Effect of bedside health education for elderly patients with fragility fracture by specialist physicians on the diagnosis and treatment of osteoporosis during hospitalization and the visiting rate to osteoporosis clinic after discharge in a high-volume orthopedic hospital [J ] . Arch Osteoporos , 2023 , 18 ( 1 ): 133 .
TSAI J N , UIHLEIN A V , LEE H , et al . Teriparatide and denosumab,alone or combined,in women with postmenopausal osteoporosis:the DATA study randomised trial [J ] . Lancet , 2013 , 382 ( 9886 ): 50 - 56 .